As shown in Figures 3A, B and Supplementary Figures 3D, E, in the CD8+ T cells-deleting LLC or B16F10 tumor-bearing mice, all the different treatments resulted in comparable tumor volume and prolong overall survival, indicating that IL-10, Ad-hTERT or IL-10+Ad-hTERT therapies did not affect the tumor development. This evidence concerns the gene CD8A and neoplasm.